Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147651 | 1.00 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL26359430 | 0.91 | ALPI (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL15679078 | 0.91 | ALPI (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2436027 | 0.91 | SLC7A5 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL15271156 | 0.90 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL14095409 | 0.88 | ALPI (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6368998 | 0.88 | ALPI (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL17460100 | 0.87 | SLC7A5 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL23542514 | 0.86 | ALPI (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL18274697 | 0.86 | ALPI (0.59) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | claimed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | claimed |
| EP-3566701-A1 | DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES | Biogen MA Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10399924-B2 | Deuterium substituted fumarate derivatives | BIOGEN MA INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2934503-B1 | DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES | BIOGEN MA INC (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-105142628-A | Deuterium substituted fumarate derivatives | BIOGEN IDEC INC | 2015-12-09 | — | — | CN | disclosed |
| EP-2934503-A1 | DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES | Biogen MA Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140194427-A1 | Deuterium Substituted Fumarate Derivatives | BIOGEN IDEC MA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014100728-A1 | DEUTERIUM SUBSTITUTED FUMARATE DERIVATIVES | BIOGEN IDEC MA INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140117280-A1 | OXYGEN ABSORBER | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140117280-A1 | OXYGEN ABSORBER | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-7754771-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-07-13 | — | — | US | disclosed |
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2010-03-18 | — | — | US | disclosed |
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2010-03-18 | — | — | US | disclosed |
| US-7674829-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-03-09 | — | — | US | disclosed |
| US-7674829-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-03-09 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399924-B2 | Deuterium substituted fumarate derivatives | FH, HTT, FAHD1 | SLC7A5 2424/4885ALPI 3981/4885PKM 1172/4885 |
| US-20140194427-A1 | Deuterium Substituted Fumarate Derivatives | FH, HTT, SDHB | SLC7A5 1277/4885ALPI 2946/4885PKM 940/4885 |
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | TSLP, HLA-DRB1, MRGPRX2 | SLC7A5 3844/4885ALPI 1218/4885PKM 4171/4885 |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | SLC7A5 1295/4885ALPI 966/4885PKM 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.